-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Business and Investments
Latest From Business and Investments
Is the early-stage IPO making a comeback?
Yesterday was the NASDAQ debut for preclinical-stage biotech Regulus (RGLS). The microRNA platform company is working in multiple therapeutic areas and planning to reach the clinic in 2014. Since the start of the 2009 post-market crash window for biotech IPOs, there have been only two preclinical biotech companies to make it to the public stage. Back in January, we saw Verastem (VSTM), at only 1.5 years of age, make it to the NASDAQ and raise Read More >
#BIF2012 Company Snapshot: Profil Institute for Translational Medicine
For the next Company Snapshot for the BIO Investor Forum, we’ve spoken with one of the presenting companies at the event, Profil Institute for Translational Medicine, Inc. To find out more about this organization and what they’re doing for biotech, please read below! You’ll be able to see their presentation onsite, Wednesday 10/10 at 9:30am in the Presidio Room. Company Snapshot What is your company’s lead product or technology? Based on collaborations with biopharma, Read More >
Virginia Bio Announces New Executive Leadership
The Virginia Biotechnology Association (Virginia Bio), the premier statewide non-profit trade association for life science industries, has named its interim executive director to the full-time position of chief executive officer. With an extensive background in the law and non-profit sectors as well as the life sciences, Jeffrey Gallagher brings leadership and policy expertise to his newly defined role, where he will be responsible for developing and executing the association’s strategic plans, prioritizing the organization’s areas Read More >
A Start-Up Model Worthy of Consideration
Biotech LLCs are getting a lot of attention lately, and perhaps rightfully so. The Wall Street Journal’s Brian Gormley recently talked to Albert L. Sokol, a partner with Edwards Wildman Palmer, about the two venture-backed biotechs – Forma Therapeutics and Viamet Pharmaceuticals – that he helped convert to LLCs. In the WSJ article – Biotech Start-Ups See Benefits from Changing Structure, Lawyer Says – Sokol describes the benefits to start-ups and their venture investors, as Read More >
2012 BIO Investor Forum: Discovery Track Snapshot
BIO’s 11th Annual BIO Investor Forum is just around the corner – it will be held October 9-10, 2012 at the Palace Hotel in San Francisco, CA. The forum, or BIF as we call it around here, is an international investor event which explores trends and opportunities in life sciences. Broadly speaking, the focus is on venture-stage growth and emerging public companies. BIO’s Alan Eisenberg said it best earlier this week: “The aim of the Read More >
